


































quality	 separation	 was	 achieved	 on	 a	 Luna	 C18	 column	 (150	 mm	 ×	 4.6	 mm,	 3	 µm)	 using
gradient	elution	at	a	flow	rate	of	1	mL/min	and	a	column	temperature	of	45	°C.	UV	detection
was	 performed	 at	 254	 nm.	 The	 validation	 was	 performed	 according	 to	 the	 International
Conference	on	Harmonization	(ICH)	guidelines.	In	addition,	the	solution	stability	and	method
robustness	 were	 examined.	 The	 method	 gives	 satisfactory	 separation	 of	 impurities	 of











Pioglitazone	 hydrochloride	 is	 an	 oral	 anti	 diabetic	 agent	
that	 acts	 primarily	 by	 decreasing	 insulin	 resistance.	
Pioglitazone	hydrochloride	is	used	in	the	management	of	type	2	
diabetes	 mellitus	 (also	 known	 as	 non‐insulin‐dependent	
diabetes	 mellitus	 [NIDDM]	 or	 adult‐onset	 diabetes).	
Pioglitazone	 hydrochloride	 selectively	 stimulates	 nuclear	
receptor	 peroxisone	 proliferator‐activated	 receptor	 gamma	
(PPAR‐gamma).	Activation	of	PPAR	gamma	receptors	regulates	
the	 transcription	 of	 insulin‐responsive	 genes	 involved	 in	 the	
control	 of	 glucose	 production,	 transport	 and	 utilization.	
Pioglitazone	 Hydrochloride,	 a	 member	 of	 the	 drug	 group	
known	as	the	thiazolidinediones	or	"insulin	sensitizers",	 is	not	
chemically	 or	 functionally	 related	 to	 the	 alpha‐glucosidase	
inhibitors,	 the	 biguanides,	 or	 the	 sulfonylureas.	 Pioglitazone	
hydrochloride	stimulates	the	uptake	of	glucose	and	fatty	acids	
into	cells	by	promoting	the	synthesis	and	expression	of	cellular	
glucose	 and	 fatty	 acid	 transporters	 [1].	 Many	 studies	 of	
pioglitazone	 demonstrated	 the	 improvement	 of	 glycemic	
control,	HbA1c,	 fasting	plasma	glucose	 levels,	 and	serum	 lipid	
profiles	 [2,3].	 Pioglitazone	hydrochloride	undergoes	 extensive	
hepatic	metabolism,	predominantly	via	cytochrome	P450	(CYP)	
2C8	system.	Its	elimination	half‐life	was	3‐7	h.	Pioglitazone	and	
its	 metabolites	 were	 excreted	 via	 urine	 (15‐30%).	 The	
remainders	 were	 excreted	 into	 bile	 and	 feces	 [4‐6].	 More	
recently,	 pioglitazone	 and	 other	 active	 thiazolidinedione	 have	
been	 shown	 to	 bind	 to	 the	 outer	 mitochondrial	 membrane	
protein	 mitoNEET	 with	 affinity	 comparable	 to	 that	 of	
pioglitazone	 for	 PPARγ	 [7‐10].	 Pioglitazone	 hydrochloride	
reduces	 insulin	 resistance	 in	 the	 liver	 and	 peripheral	 tissues;	
increases	 the	expense	of	 insulin‐dependent	glucose;	decreases	





reported	 an	 analytical	 method	 for	 the	 simultaneous	
quantitation	 of	 pioglitazone	 and	 its	 metabolites	 in	 human	
serum	using	HPLC/UV	[11].	Yamashita	et	al.	have	developed	a	
HPLC	 method	 for	 determination	 of	 pioglitazone	 and	 its	
metabolites	 in	 human	 serum	 and	 urine.	 In	 this	 method	
separation	was	 achieved	 by	 inertsil	 ODS‐2	 column	 (150	×	4.6	
mm)	 with	 5	 µm	 particle	 size,	 mobile	 phase	 consists	 of	
phosphate	 buffer,	 methanol	 and	 acetonitrile;	 gradient	 elution	
was	performed	at	a	wavelength	269	nm	[12].	Radhakrishna	et	
al.	 reported	 determination	 of	 pioglitazone	 hydrochloride	 in	









method	 for	 simultaneous	 determination	 of	 pioglitazone	 and	
glimipride	[15].	Sripalakit	et	al.	have	reported	a	HPLC	method	
for	 the	 determination	 of	 pioglitazone	 in	 human	 plasma	 using	
UV	detection	and	its	application	to	a	pharmacokinetic	study.	In	
this	method	 chromatographic	 separation	was	 achieved	with	 a	
RP	 Apollo	 C18	 Column	 and	 mobile	 phase	 consisting	 of	
methanol,	 acetonitrile,	 phosphate	 buffer,	 at	 a	wavelength	 269	
nm	 [16].	 Lofty	 Saber	 reported	 a	HPLC	method	 for	 determina‐
tion	of	pioglitazone	hydrochloride	in	tablets	[17].	Tahmasebi	et	
al.	have	studied	an	extraction	of	trace	amounts	of	pioglitazone	
with	 hollow	 fiber	 liquid	 phase	 micro	 extraction	 by	 HPLC‐UV	
detection	in	biological	fluids	[18,19].	Although,	to	date	there	is	
no	 method	 reported	 for	 determination	 of	 process‐related	
substances	 of	 pioglitazone	 hydrochloride	 in	 the	 literature	
(Figure	 1).	 The	 present	 study	 is	 aimed	 at	 separation	 and	












An	 integrated	 HPLC	 system	 with	 computer	 based	
chromatography	 software	 (empower)	 was	 used.	 The	 Water’s	






Pioglitazone	 hydrochloride	 working	 standard	 and	 its	
process	 related	 impurities	 were	 synthesized	 at	 Pharmazell	
Research	 Centre,	 Visakhapatnam	 (India)	 and	 obtained	 as	 gift	
samples.	 HPLC	 grade	 acetonitrile	 was	 obtained	 from	 Merck.	
Analytical	grade	ammonium	acetate,	acetic	acid	was	used.	High	
purity	water	was	prepared	by	using	Milli‐Q	Elix	and	then	using	








water,	 pH	 was	 adjusted	 to	 4.6±0.05	 with	 acetic	 acid,	 filtered	

















mg	 of	 pioglitazone	 hydrochloride	 and	 transferred	 into	 50	mL	






About	 50	 mg	 of	 sample	 was	 weighed	 accurately	 and	
transferred	into	50	mL	volumetric	flask,	add	30	mL	of	diluent,	






related	 impurities	 (impurity	 A,	 B	 and	 C)	 were	 weighed	
accurately	and	transferred	into	100	mL	volumetric	flask,	60	mL	
of	 diluent	 was	 added,	 sonicated	 for	 10	 min	 to	 dissolve	 the	
compounds	 and	 the	 volume	 was	 made	 up	 to	 100	 mL	 with	
diluent.	 5	 mL	 of	 this	 solution	 was	 made	 up	 to	 50	 mL	 with	
diluent	to	get	a	concentration	of	38	µg/mL.	This	impurity	stock	






determination	 of	 pioglitazone	 hydrochloride	 and	 its	 process	
related	 impurities,	 different	mobile	 phases	 and	 columns	were	
employed	 to	 achieve	 the	 best	 separation	 and	 resolution.	 The	
method	 development	 was	 initiated	 with	 C18	 column	 using	 a	
mobile	 phase	 containing	 water	 and	 acetonitrile	 as	 organic	
modifier.	Broad	peaks	were	observed	with	this	mobile	phase.	In	
the	 above	 mobile	 phase	 water	 was	 replaced	 with	 phosphate	
buffer.	 Peak	 symmetry	 was	 not	 good.	 To	 improve	 the	 peak	
shapes,	 ammonium	 acetate	 buffer	 was	 used	 in	 place	 of	
phosphate	 buffer.	 It	 gave	 sharp	 peaks	 but	 the	 problem	 is	
impurities	 are	 merging.	 Compounds	 are	 having	 varying	
polarities.	 A	 gradient	 elution	 mode	 was	 tried;	 many	
experiments	 were	 conducted	 by	 using	 different	 gradient	
programs	 and	 columns	 while	 optimizing	 the	 pH	 of	 buffer,	
buffer	 concentration,	 organic	 modifier	 strength	 and	
wavelength.	 Finally	 the	 best	 results	 were	 observed	 using	 a	
column	 C18	ODS	 (150	 ×	 4.6	mm),	mobile	 phase	 consisting	 of	








Name	 RT	 RRT Resolution	(Rs) Theoretical	plates	(N)	 Peak	symmetry	(As)
Impurity‐A	 3.478	 0.41 ‐ 2944.3 1.1	
Impurity‐B	 10.770	 1.28	 5.8	 13461	 1.0	
Impurity‐C	 18.000	 2.15	 25.1	 122171.6	 1.1	









































ratio	 (20:80,	 v:v)	 at	 a	 flow	 rate	 of	 1.0	 mL/min.	 According	 to	
gradient	elution	program	0‐7	min	(100%	A),	7‐20	min	(100%	
B),	 20‐21	 min	 (100%	 A).	 In	 the	 above	 chromatographic	











the	 suitability	 of	 the	 proposed	 procedures	 for	 the	 intended	
purpose.	 More	 specifically,	 it	 is	 a	 matter	 of	 establishing	
documented	 evidence	 providing	 a	 high	 degree	 of	 assurance	
with	 respect	 to	 the	 consistency	 of	 the	method	 and	 results	 to	
evaluate	 the	 product	 against	 defined	 specifications.	 The	
validation	 parameters	 viz.,	 specificity,	 accuracy,	 precision,	
linearity,	 limit	 of	 detection,	 limit	 of	 quantitation,	 robustness,	





This	 is	 an	 integral	 part	 of	 development	 of	 a	
chromatographic	 method	 to	 verify	 that	 the	 resolution	 and	
reproducibility	 of	 the	 system	 are	 adequate	 enough	 for	 the	
analysis	 to	 be	 performed.	 It	 is	 based	 on	 the	 concept	 that	 the	
equipment,	 electronics,	 analytical	 operations	 and	 samples	
constituting	an	 integral	system	could	be	evaluated	as	a	whole.	
Parameters	 such	 as	 plate	 number	 (N),	 asymmetry	 or	 tailing	
factors	 (As),	 relative	 retention	 time	 (RRT),	 resolution	 (Rs)	 and	
reproducibility	 (%	 R.S.D),	 retention	 time	 were	 determined	
(Table	 1).	 These	 parameters	 were	 determined	 during	 the	
analysis	 of	 a	 "sample"	 containing	 the	 main	 components	 and	






Specificity	 is	 the	 ability	 of	 the	 method	 to	 measure	 the	
analyte	response	 in	presence	of	 its	process	related	 impurities.	
The	specificity	of	 the	developed	HPLC	method	was	performed	
by	 injecting	 blank	 solution	 and	 standard	 solution	 spiked	with	
process‐related	 impurities	 separately.	 The	 chromatogram	 of	
drug	 with	 impurities	 was	 compared	 with	 the	 blank	
chromatogram,	 to	 verify	 the	 blank	 interference.	 No	 peak	was	
observed	 at	 the	 retention	 time	 of	 pioglitazone	 hydrochloride	
and	 its	 impurities.	 Hence	 the	 method	 is	 specific	 for	 the	






from	 LOQ	 to	 2.25	 μg/mL	 (150%	 of	 specification	 limit)	 were	
prepared	 and	 analyzed	 in	 triplicate.	 In	 order	 to	 demonstrate	
the	 linearity	 of	 detector	 response	 for	 pioglitazone	
hydrochloride	and	 its	 impurities,	 the	 linearity	plot	was	drawn	
taking	the	concentration	on	X	axis	and	the	mean	peak	area	on	Y	
axis.	 The	 data	 was	 subjected	 to	 statistical	 analysis	 using	 a	










































































































pioglitazone	 hydrochloride	 drug	 substance	 spiked	 with	
impurities	 at	 three	 different	 concentration	 levels	 of	 50%,	
100%,	and	150%	of	each	in	triplicate	at	the	specified	limit.	The	
mean	recoveries	of	all	the	impurities	were	calculated	(Table	6).	
The	%	recovery	obtained	 is	well	within	 the	 limit	of	85‐115%.	












Name	 Spike	Level	(%)	 Concentration	spiked	(μg/mL)	 Concentration	recovered	(μg/mL)	 %	Recovery	a	
Impurity‐A	 50	 0.76	 0.83 109.2
100	 1.52	 1.64 107.9
150	 2.28	 2.49 109.2
Impurity‐B	 50	 0.75	 0.72 96.0
100	 1.50	 1.42 94.7
150	 2.25	 2.13 94.7
Impurity‐C	 50	 0.78	 0.88	 112.8	
100	 1.56	 1.68	 107.7	







Impurity‐A	 0.58	 0.53±0.09 0.51±0.06	
Impurity‐B	 0.61	 0.63±0.05 0.65±0.09	
Impurity‐C	 0.88	 0.86±0.07 0.91±0.09	




S.	No	 Name		 Concentration	(µg/mL)	 Observed	signal	to	noise	ratio	
1	 Impurity‐A	 0.187 9.9
2	 Impurity‐B	 0.376 10.2
3	 Impurity‐C	 0.377 10.4




S.	No	 Name		 Concentration	(µg/mL) Observed	signal	to	noise	ratio	
1	 Impurity‐A	 0.061 2.9
2	 Impurity‐B	 0.124	 3.1	
3	 Impurity‐C	 0.124	 3.4	






the	 standard	 solution	 six	 times	 and	percent	 relative	 standard	
deviation	(%	R.S.D)	for	area	of	pioglitazone	hydrochloride	peak	
was	calculated.	 It	was	 found	 to	be	 less	 than	2.0%	(R.S.D).	The	
precision	 of	 the	 method	 for	 the	 determination	 of	 impurities	
related	 to	 pioglitazone	 hydrochloride	 was	 studied	 for	
repeatability	 and	 intermediate	 precision	 at	 100%	 level.	
Repeatability	 was	 demonstrated	 by	 analysing	 the	 standard	
solution	 spiked	with	 impurities	 for	 six	 times.	 The	%R.S.D	 for	
peak	 area	 of	 each	 impurity	 was	 calculated.	 Intermediate	
precision	 was	 demonstrated	 by	 analysing	 same	 sample	 of	
pioglitazone	 hydrochloride	 by	 two	 different	 analysts	 on	 two	
different	 days	 (Inter‐day).	 Intra‐day	 variations	 of	 impurities	
related	to	pioglitazone	hydrochloride	are	expressed	in	terms	of	
%	 R.S.D	 Values.	 Repeatability	 and	 intermediate	 precision	 for	






The	 limit	 of	 detection	 (LOD)	 and	 limit	 of	 quantification	
(LOQ)	 represent	 the	 concentration	 of	 the	 analyte	 that	 would	
yield	 signal‐to‐noise	 ratios	 of	 3	 for	 LOD	 and	 10	 for	 LOQ,	
respectively.	LOD	and	LOQ	were	determined	by	measuring	the	
magnitude	 of	 analytical	 background	 by	 blank	 samples	 and	







To	 determine	 the	 robustness	 of	 the	 developed	 method,	
chromatographic	 conditions	 were	 deliberately	 altered.	 The	
parameters	 selected	were	 change	 in	 flow	 rate	 (±0.2	mL/min),	
change	in	pH	of	the	buffer	(±0.2),	change	in	the	ratio	of	mobile	
phase	 (±	4%)	and	change	 in	 the	 column	 temperature	 (±5	 °C),	
the	rest	of	 the	chromatographic	conditions	 for	each	alteration	
study	 was	 kept	 constant.	 In	 all	 the	 deliberately	 varied	
chromatographic	 conditions,	 no	 significant	 change	 was	









A	 new	 gradient	 RP‐HPLC	 method	 was	 developed	 for	 the	
separation	and	determination	of	process	 related	 impurities	 in	
pioglitazone	hydrochloride	and	validated	as	per	ICH	guidelines.	
The	 method	 was	 found	 to	 be	 simple,	 selective,	 precise,	
sensitive,	 robust	 and	 accurate.	 Therefore,	 this	method	 can	 be	
used	 for	 routine	 testing	 as	 well	 as	 stability	 analysis	 of	
pioglitazone	 hydrochloride	 drug	 substance.	 All	 statistical	
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